[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Waterloo\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":180},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,76,99,131,157],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":37,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100619218","brain-stimulation-effects-on-orientation-and-mobility-skills-in-adults-with-vision-impairment-100619218",false,"NCT07341763","Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment","A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate Non-invasive Brain Stimulation Effects on Orientation and Mobility Performance in Adults With Visual Impairments","Inclusion Criteria:\n\n* Are healthy, capacitated adults with binocular constricted visual field loss (due to either retinitis pigmentosa (RP), rod-cone dystrophy, or advanced glaucoma) resulting in functional vision losses. These individuals with visual impairments can be those who have been previously trained by an Orientation and Mobility (O\\&M) specialist to independently travel with the long white cane daily (since the length of the white cane and tip at the base are based on personal preference, they should be willing to use their own white cane for the study), and those who do not necessarily use a cane for travelling.\n* Have binocular visual acuity or best corrected binocular visual acuity no worse than 6\u002F12 or 20\u002F40 or +0.30 logMAR (inclusive) with no eccentric viewing and binocular visual fields no better than 50 degrees in total in each eye as given by the Humphrey Field analyzer and no better than 50 degrees binocularly as given by arc perimeter test. The Humphrey Field Analyzer measures static visual field test, whereas the Arc perimeter test measures kinetic visual field test. Measuring kinetic and static visual field would promote a greater understanding of the individual's daily performance.\n* Are over the age of 18 (inclusive) and has full legal capacity to provide informed consent.\n* Have read and fully comprehends the information in the consent letter.\n* Are willing and capable of adhering to instructions and maintaining the outlined appointment schedule.\n\nExclusion Criteria:\n\n* Are involved in other recent eye-related studies, either clinical or research-related. To be eligible they would have to wait at least one week for studies not involving brain stimulation, and four weeks for studies in which they receive brain stimulation before they could participate in this study.\n* Have been diagnosed with dementia or self-reported dementia with no formal diagnosis.\n* Have been diagnosed with a cognitive impairment or self-reported cognitive impairment with no formal diagnosis.\n* Have been diagnosed with physical or motor impairments resulting in walking and\u002For balancing issues or self-reported physical or motor impairments resulting in walking and\u002For balancing issues with no formal diagnosis.\n* Have been diagnosed with vestibular disorders or dysfunctions which affects one's balance and\u002For mobility or self-reported vestibular disorders or dysfunctions which affects one's balance and\u002For mobility with no formal diagnosis.\n* Are unable to follow the researcher's instructions.\n* Are anticipating treatment (including ocular surgery) for any eye disease within the duration of the study.\n* Have any ocular pathology in addition to retinitis pigmentosa (RP), rod-cone dystrophy, or advanced glaucoma, which can diminish their visual acuity and\u002For their visual field, however wearing glasses or contact lenses, as well as mild cataract of grade 2 or below is acceptable.\n* Have severe hearing impairment.\n* Are pregnant or trying to get pregnant.\n* Fit any of the typical contraindicators for brain stimulation. See contraindicator section below.\n\nFor all participants the contraindications for brain stimulation are:\n\n* Diagnosed with epilepsy or have previously experienced an epileptic seizure.\n* Implanted medication pump or implanted electronic device, including defibrillator or pacemaker.\n* Any metal implants in the head (excluding tooth fillings).\n* Active electric implants anywhere in the body (especially the head region).\n* On psychoactive medication for any psychiatric or neurological conditions including but not limited to depression and schizophrenia.\n* Areas of sensitive skin located on the face or head, or a skin condition on the face, or regularly use medication to alleviate skin irritation on the face.\n* Recurring headaches.\n* Previous head injury or skull fracture or head\u002Fbrain surgery.\n* Heart disease, neurological condition, or a history of cardiac or neurological surgery.\n* Current or historical cancerous or noncancerous brain tumor, or other abnormalities in brain structure.","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","This pilot clinical trial evaluates whether non-invasive brain stimulation improves the orientation and mobility (O\\&M) skills of individuals with constricted visual fields in both eyes. The study is composed of three visits. The first visit is meant to confirm eligibility by performing a few clinical tests. Eligible participants will then complete two additional visits, one in which the participants receive active stimulation, and one in which the participants receive placebo (sham) stimulation. Stimulation will be administered in a randomized, double-blind order. To evaluate improvement, various measures of O\\&M performance will be assessed on a standardized obstacle course featuring static natural and artificial obstacles at defined intervals after the intervention. We hypothesize that the application of hf-tRNS to V1 will improve the orientation and mobility skills of individuals with constricted visual fields immediately following stimulation as a results of enhanced periphery through modulation of the mechanisms responsible for crowding, thereby reducing crowding effects and improving contrast for individuals with rod-cone dystrophy and RP (genetic conditions), whereas for individuals with glaucoma (a neurogenerative condition), any improvement noted would be attributed to be enhanced processing of visual signal in the affected periphery. The results will inform the design of a future, larger-scale study.",[26,27,28,29,30,31,32,33,34,35,36],"Retinitis Pigmentosa (RP)","Rod Cone Dystrophy","Visually Impaired Persons","Peripheral Visual Field Defect of Both Eyes","Low Vision, Both Eyes","Vision Loss Partial","Orientation","Mobility Difficulty","Mobility Limitation","Mobility and Independence","Glaucoma",[26,38,39,28,29,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63],"Rod Cone dystrophy","Advanced Glaucoma","Low Vision, Both eyes","Brain stimulation","tES","tRNS","hf-tRNS","transcranial electrical stimulation","transcranial random noise stimulation","high-frequency transcranial random noise stimulation","Long white cane","white cane","mobility cane","walking","orientation and mobility","orientation","mobility","low vision","vision loss partial","occipital pole","primary visual cortex","V1","neuroplasticity","mobility difficulty","mobility limitation","mobility and independence","RECRUITING","2026-06-30",{"date":67,"type":68},"2026-07-01","ACTUAL",{"date":67,"type":20},{"date":71,"type":20},"2027-08-31",{"name":73,"class":74},"University of Waterloo","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":75},"100627634","phase-4-comparison-of-ocular-lubricants-in-people-with-symptoms-of-dry-eye-100627634","NCT07451184","Comparison of Ocular Lubricants in People With Symptoms of Dry Eye","Symptomology Changes With Systane PRO PF Versus Thealoz Duo","SPHINX","Inclusion Criteria:\n\n1. Are at least 18 years of age and have full legal capacity to volunteer;\n2. Have understood and signed an institutional review board (IRB)\u002F independent ethics committee (IEC) approved informed consent form;\n3. Are willing and able to attend all study visits as required per protocol;\n4. Are willing to discontinue use of all habitual artificial tear supplements and use only the study drops as directed for the entire study duration;\n5. Have dry eye symptomatology as per Tear Film \\& Ocular Surface Society Dry Eye WorkShop (TFOS DEWS) II definition:\n\n   * Have an Ocular Surface Disease Index (OSDI) score ≥13;\n6. Have an absence of active\\* anterior segment disease;\n7. Have not worn contact lenses for the previous 14 days before screening, and are willing to not wear contact lenses for the duration of the study;\n8. Are correctable to a visual acuity of +0.20 LogMAR or better (in at least one eye) with refraction results.\n\nExclusion Criteria:\n\n1. Have taken part in an interventional clinical study within the previous 14 days before screening;\n2. Are participating in any concurrent ocular or interventional clinical trial;\n3. Have any active\\* ocular inflammation, infection, or are using ocular topical treatment (other than dry eye drops);\n4. Started any systemic medication known to cause dry eye (e.g., anti-histamine, antidepressants, benzodiazepines, etc.) within 30 days before screening. Stable dosing for \\>30 days before screening is allowed, but changes (including commencing new) of dosing of such medication within the study period would lead to early exit from the study;\n5. Had any ocular injury or surgery within the 1 year prior to screening, nor have ocular surgery planned\u002F anticipated;\n6. Have biomicroscopy signs of grade 3 or more (Efron scale);\n7. Have known sensitivity to the diagnostic pharmaceuticals or to any ingredients in the study products;\n8. Are pregnant, lactating or planning a pregnancy at the time of enrolment;\n9. Are a member of the Centre for Ocular Research \\& Education directly involved in this study (on the delegation log);\n10. Are an employee of Alcon.",{"count":85,"type":20},100,[87],"PHASE4","Ocular dryness and discomfort are symptoms commonly associated with dry eye. Lubricating eye drops, also called artificial tears, are often used to moisten the eye and provide relief from these symptoms. There are currently several types of lubricating eye drops available, differing in their ingredients, consistency, and recommended frequency of application. The aim of this study is to compare the effectiveness of two lubricating eye drops that differ in their ingredients and recommended frequency of application. The goal is to see whether they perform the same or if one of them provides better relief for people with dry eye symptoms. One of the eye drops is commercially available in Canada, the other one is not commercially available in Canada and therefore considered an investigational eye drop. This eye drop is available in the United States of America. In this study, participants will use one drop twice per day and the other drop four times per day. Each product will be used for 4 weeks and all participants will use both products (one after the other). There will be a 2-week period of no drops between the two study products. Before starting each drop and after 4 weeks of drop use, we will assess the eyes of the participants and ask them how their eyes feel. Participants will also be asked to answer a series of questions regarding the drops. Participants will encounter procedures that they normally experience in an eye care setting. The results will help the funding company to better understand the performance of the products used in this study. It may also help eyecare practitioners in managing their patients with dry eye symptoms. The hypothesis is that the drop used twice a day will be non-inferior to the drop used 4 times per day for the change in dry eye symptoms (assessed with the Ocular Surface Disease Index questionnaire) after 4 weeks of use.",[90],"Dry Eye Symptoms","2026-04-23",{"date":93,"type":68},"2026-04-28",{"date":95,"type":68},"2026-02-23",{"date":97,"type":20},"2027-05-23",{"name":73,"class":74},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},"100421022","learning-study-improving-vision-in-adults-with-macular-degeneration-100421022","NCT04762368","Learning Study: Improving Vision in Adults With Macular Degeneration","Improving Vision in Adults With Macular Degeneration, Study 2: The Effect of Concurrent Perceptual Learning and Brain Stimulation","Inclusion Criteria:\n\n1. Diagnosis of AMD (age 60+) or JMD (current age 18+).\n2. Visual acuity (VA); between 6\u002F9-6\u002F96 in the better eye\n3. Best-corrected near visual acuity of 4.0M at 40 cm or better in the better eye\n4. Stable vision in previous 3 months (patient report)\n5. Central vision loss\n\nExclusion Criteria:\n\n1. Diagnosed dementia.\n2. Not fluent in reading English (Waterloo) or Chinese characters (Hong Kong).\n3. Any ocular surgery (including anti-vegF injections) within the duration of the study, except for: A. Chronic and continuous injections for at least 1 year. B. Injections stopped at least 2 months before participation. C. Injections in the untested eye\n4. Ocular pathology other than JMD or AMD that can significantly reduce central vision. Example: mild cataract of grade 2 or below is acceptable\n5. Severe hearing impairment.\n6. Contraindications for brain stimulation",{"count":107,"type":20},30,[23],"The purpose of this study is to test whether a kind of brain stimulation called anodal transcranial direct current stimulation (a-tDCS) can be combined with perceptual learning to improve the ability of people with age-related macular degeneration (AMD) or juvenile macular degeneration (JMD) to read words presented to them on a computer screen better than if perceptual learning alone were used.\n\nIn addition, secondary measures of visual acuity will also be examined to determine whether brain stimulation can allow patients to resolve finer details of an image. The proposed treatment is the application of a-tDCS onto the participant's head, with brain stimulation aimed at Primary Visual Cortex toward the occipital pole, while patients undergo six separate sessions of training. The investigators will test the ability of participants to read words before the start of the training sessions (pre test) and after the completion of all training sessions (post test). This is a between-subjects design, and half of the participants will receive true stimulation, and the other half will receive sham stimulation. The difference between the pre and post tests when receiving active stimulation will be compared to the difference when receiving sham stimulation, because the sham stimulation is not expected to influence reading beyond a placebo. The aim of the study is to examine the potential of concurrent brain stimulation and perceptual learning as an effective treatment for macular degeneration that may be used in conjunction with more traditional eye-based interventions. The investigators hypothesize that the brain stimulation will enable higher performance in the reading task after and secondary measures after perceptual training due to an increase in the cortical excitability of the stimulated brain cells.",[111],"Macular Degeneration",[111,113,114,115,116,117,118,119,120,121],"Brain Stimulation","Psychophysics","Reading","tDCS","RSVP","Visual Acuity","Uncrowded Visual Acuity","Crowded Visual Acuity","Contrast Sensitivity","2026-01-21",{"date":124,"type":68},"2026-01-22",{"date":126,"type":68},"2021-02-13",{"date":128,"type":20},"2026-12",{"name":73,"class":74},2,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":139,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":21,"phases":142,"briefSummary":143,"conditions":144,"keywords":147,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":75},"100615136","chiropractor-delivered-virtual-intervention-after-vertebral-fracture-100615136","NCT07288684","Chiropractor Delivered Virtual Intervention After Vertebral frActure","Chiropractor Delivered Virtual Intervention After Vertebral frActure (VIVA)","VIVA","Inclusion Criteria:\n\n* Over the age of 50 (men or post-menopausal women)\n* Have had a vertebral fracture in the past two years\n* Willing to participate in twelve (12) virtual rehabilitation sessions for 10 weeks\n* Have access to internet and a smart device with a camera and microphone\n\nExclusion Criteria:\n\n* Cauda equina syndrome or spinal cord injury\n* Had a traumatic fracture (i.e., car accident)\n* An active infection\n* Active inflammatory arthritis with a flare up within the past two years\n* An inability to follow two-step commands or understand instructions and are without a caregiver to support participation\n* Been participating in a similar rehabilitation program for vertebral fractures delivered by a physical therapist, exercise physiologist or kinesiologist and includes exercise\n* Any surgeries planned or health problems that might cause their health to change significantly in the next 3 months","50 Years",{"count":141,"type":20},15,[23],"This study will determine feasibility of a chiropractor delivered virtual intervention for individuals following osteoporotic vertebral fracture.\n\nThis pilot trial will have two parallel groups with a 1:1 ratio. Participants will be randomized to: 1) immediate receipt; or 2) waitlist usual care control and delayed receipt of VIVA 10 weeks post-randomization.\n\nVIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics.\n\nA chiropractor (DC) completes a virtual assessment and then leads twelve 1:1 virtual sessions (via Zoom) over eight weeks. Sessions start with brief education on a topic (e.g., safe movement, pain management, exercise, nutrition), followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning.\n\nThis trial will be considered feasible if a) we recruit 14 people in eight months; b) 80% of participants complete the trial; and c) exercise adherence is 75%.",[145,146],"Osteoporosis","Vertebral Fracture",[148],"Rehabilitation","2025-12-03",{"date":151,"type":68},"2025-12-17",{"date":153,"type":68},"2025-10-20",{"date":155,"type":20},"2026-06-01",{"name":73,"class":74},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":164,"sex":16,"minAge":17,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":168,"phases":4,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":75},"100583565","validation-and-testing-of-a-novel-continuous-glucose-and-continuous-ketone-monitoring-device-in-healthy-volunteers-100583565","NCT06877975","Validation and Testing of a Novel Continuous Glucose and Continuous Ketone Monitoring Device in Healthy Volunteers","Validation and Testing of a Novel CGM-CKM Device in Healthy Volunteers","The age range for the healthy volunteers (HVs) will be between 18 and 45 years old and with no family history of Diabetes (T1D or T2D, specifically biological parents and siblings).\n\nExclusion criteria included: (i) currently taking any medications (except for birth control for females); (ii) following a low-carbohydrate diet or consuming nutritional ketone supplements; (iii) considered competitive athlete engaged in competition or intensive training, (iv) have been diagnosed with Diabetes (T1D or T2D), hypertension, cardiovascular disease, kidney disease, and thyroid disorder. (v) Having an allergy to any of the ingredients in the products used in the study, which will be explained to you in detail.",true,"45 Years",{"count":167,"type":20},16,"OBSERVATIONAL","Diabetic ketoacidosis (DKA) is a severe complication of type 1 diabetes (T1D) that can have life-threatening consequences. It occurs when there is a high level of glucose in the blood and the body produces excessive amounts of ketone bodies. To manage this condition, individuals with T1D need to constantly monitor their levels of ketone bodies and glucose. While continuous glucose monitoring (CGM) devices have made significant advancements in providing non-invasive or minimally invasive glucose measurements, there has been little progress in developing methods for continuous monitoring of ketone bodies (CKM). Currently, the commonly used approaches involve self monitoring with commercially available blood or urine strips. However, these tools have limited adoption, provide only single time point measurements, and can be costly for some patients.\n\nIn our project, which is funded by Breakthrough T1D (2-SRA-2022-1167-M-B), we address this challenge by utilizing a minimally invasive biosensor based on hydrogel microneedle (HMN). This biosensor enables simultaneous and continuous measurement of the primary biomarker for ketone formation, 3-β hydroxybutyrate (β-HB), as well as glucose levels. By doing so, we intend to reduce the risk of diabetic ketoacidosis in patients with T1D. We plan to test the developed CGM-CKM device on human subjects, including both healthy volunteers (HV) and patients with T1D. The HV testing will take place at the laboratory of Dr. Poudineh and Dr. Devries-Aboud in Waterloo, while the validation involving patients with T1D will be conducted in collaboration with Dr. Lal at Stanford.",[171],"Diabetes Ketoacidosis","2025-03-10",{"date":174,"type":68},"2025-03-14",{"date":176,"type":20},"2025-03-30",{"date":178,"type":20},"2025-08-30",{"name":73,"class":74},""]